India Dry Age-Related Macular Degeneration (AMD) Market Overview
As per MRFR analysis, the India Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 220 (USD Million) in 2024.The India Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 240(USD Million) in 2025 to 600 (USD Million) by 2035. The India Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 8.687% during the forecast period (2025 - 2035).
Key India Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted
The India Dry Age-Related Macular Degeneration (AMD) Market is witnessing several important market trends influenced by the growing elderly population and increasing awareness of ocular health. As the elderly demographic in India expands, more individuals are affected by vision-related issues, making AMD a significant public health concern. The government's initiatives to promote eye health and regular screenings are helping to raise awareness about AMD, which in turn is driving the demand for diagnostic tools and treatment options.
Furthermore, the rising income levels and changing lifestyles have led to an increase in health spending among the population. Opportunities exist to explore innovative treatment modalities and enhanced diagnostic techniques tailored to the Indian context. The adaptation of advanced technologies for local use, such as telemedicine and mobile health applications, presents a promising avenue for improving access to AMD care. Additionally, there is a significant need for affordable treatment options, including nutritional supplements and minimally invasive procedures, which can cater to the diverse income levels across the population. Recent times have seen an uptick in research and development efforts directed towards AMD, with both public and private sectors investing in studies that aim to better understand the disease and its treatment.
Specific approaches towards AMD therapy are being developed in India owing to the expanding pharmaceutical and biotechnology industries in the country. These factors form the basis of the multidisciplinary approach which deals with the problems posed by Dry AMD in India. Collaborations between educational and health institutions are very important for innovation in this area, which certainly demonstrates an attempt to manage AMD issues within the Indian healthcare system.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
India Dry Age-Related Macular Degeneration (AMD) Market Drivers
Increasing Prevalence of Age-Related Macular Degeneration (AMD) in India
The rising prevalence of Age-Related Macular Degeneration (AMD) in India is a significant driver for the India Dry Age-Related Macular Degeneration (AMD) Market Industry. According to the National Programme for Control of Blindness and Visual Impairment (NPCBVI), around 7.6 million people in India are affected by AMD, with a projected annual increase due to the aging population. With India's elderly population expected to reach 300 million by 2030, focusing on prevention, awareness, and treatment approaches will be essential.
The Indian government has recognized the need for comprehensive eye health care, which emphasizes early detection and management of AMD, thus catalyzing market growth. Furthermore, established organizations such as the All India Ophthalmological Society have been advancing research and awareness initiatives to tackle the rising cases of AMD, underlining the urgency and potential for market expansion. Increasing governmental and non-governmental efforts to manage AMD signify a crucial market growth factor.
Technological Advancements in AMD Treatments
Technological advancements in treatments for AMD are propelling growth in the India Dry Age-Related Macular Degeneration (AMD) Market Industry. The emergence of innovative therapies such as anti-VEGF injections and gene therapy has shown significant efficacy in combating the effects of AMD. Recent studies indicate that the use of intravitreal injections can reduce the risk of vision loss by up to 50%. Organizations like the Indian Health Ministry are supporting the integration of these advanced treatments into healthcare policies, ensuring broader accessibility for patients.Collaborations between healthcare systems and technology firms are further enhancing treatment options, fostering a conducive environment for the growth of the AMD market in India.
Growing Awareness and Screening Initiatives for Eye Health
Growing awareness and screening initiatives for eye health in India have significantly contributed to the growth of the India Dry Age-Related Macular Degeneration (AMD) Market Industry. Government campaigns, such as those initiated by NPCBVI, have focused on educating the public about the importance of regular eye check-ups and early detection of AMD. The uptake of eye screening programs has increased, with reports showing nearly 20% of the urban population participating in annual eye examinations, according to the Vision 2020 initiative.NGOs and eye care associations have also been pivotal in conducting awareness programs, leading to a rise in early diagnosis and intervention, which directly increases the demand for AMD-related treatment options.
Supportive Government Policies and Funding for Eye Health
Supportive government policies and dedicated funding for eye health are critical drivers of the India Dry Age-Related Macular Degeneration (AMD) Market Industry. The Indian government has allocated resources to enhance eye care services under the National Health Mission, focusing on reducing the burden of visual impairment caused by AMD. Increased allocation, estimated to enhance the existing healthcare budget by 15%, aims to improve access to diagnosis and treatment facilities nationwide.Collaborations with organizations like the World Health Organization and local health boards are strengthening policy frameworks and initiatives, indicating strong government backing that favors the AMD sector’s growth. This environment promotes investment in research and treatment infrastructure, further stimulating market expansion.
India Dry Age-Related Macular Degeneration (AMD) Market Segment Insights
Dry Age-Related Macular Degeneration (AMD) Market Stage Insights
The India Dry Age-Related Macular Degeneration (AMD) Market segmentation around the Stage dimension reveals significant insights into the prevalence and impact of this condition on the population. Age-related macular degeneration is primarily classified into three stages: early, intermediate, and late, each reflecting varying levels of severity and visual impairment potential. The early stage is often asymptomatic, yet it serves as a crucial phase where early intervention can help slow down the progression of the disease.
This stage is characterized by the presence of drusen, or yellow deposits, under the retina, which suggest underlying retinal changes. The importance of this phase lies in the opportunity for preventive measures that can significantly influence patient outcomes, as awareness and management at this stage can limit future complications.
Moving to the intermediate stage, this phase exhibits noticeable changes in vision, and patients may begin experiencing blurred vision or difficulty in reading. This stage is significant as it represents a critical juncture where medical attention can greatly affect the disease trajectory. Nutritional intervention, alongside advanced treatments available in the market, can help retain vision longer, showcasing the shifting trends towards preventative eye care in India. Moreover, understanding this stage helps healthcare providers to strategize their approach educating patients about regular eye exams and implementing lifestyle changes that may mitigate further risks.
In contrast, the late stage of age-related macular degeneration poses the highest threat to vision, often culminating in severe visual impairment. This stage is marked by significant damage to the macula, resulting in the loss of central vision which dramatically impacts daily activities such as reading, driving, and recognizing faces. The late stage tends to demand higher healthcare engagement and forms a crucial focus for healthcare policies given the aging population in India. With increasing life expectancy and a growing elderly demographic, the late stage reflects a pressing public health concern and necessitates robust interventions, including specialized treatment options and home care services.
The trends within these stages highlight a broader societal shift towards addressing vision-related health challenges within India. Healthcare providers and policymakers are increasingly recognizing the need for comprehensive care strategies that encompass early detection, community awareness programs, and access to therapeutic modalities. Moreover, emerging technologies in diagnostics and treatment present considerable opportunities in enhancing patient care while also driving market growth in the India Dry Age-Related Macular Degeneration (AMD) Market.
These insights underline not only the importance of understanding each stage of dry AMD but also the interconnectedness of healthcare advancements, community education, and public health initiatives aimed at curtailing the impact of this progressive disease in India.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights
The India Dry Age-Related Macular Degeneration (AMD) Market exhibits notable dynamics across various age groups, especially as the population ages and the prevalence of this condition increases. Individuals above 75 years form a significant proportion of those affected by AMD, as age is a primary risk factor. This age category often has limited access to comprehensive eye care, which underscores the importance of expanding health resources and awareness campaigns tailored to their needs. In the group above 60 years, the prevalence remains high, indicating a growing demand for preventive care and treatment options.
This age bracket is also characterized by an increasing interest in innovative healthcare solutions that improve quality of life for individuals facing vision impairments. While the above 40 segment constitutes a smaller part of the patient demographic, early diagnosis and intervention in this category can lead to better management of AMD symptoms, representing a crucial opportunity for healthcare providers to engage with younger patients. Thus, the segmentation by age group within the India Dry Age-Related Macular Degeneration (AMD) Market reveals distinct needs and opportunities for health services, directly influencing market growth and development strategies.
Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights
The Diagnosis and Treatment segment of the India Dry Age-Related Macular Degeneration (AMD) Market plays a crucial role in managing this prevalent eye condition that significantly affects the aging population. As a country with a rapidly growing elderly demographic, the demand for effective diagnostic solutions and treatments in the context of AMD is on the rise. Diagnosis options often include advanced imaging techniques that enable early detection, which is vital in preventing vision loss. The treatment sector encompasses various therapeutic modalities, including anti-VEGF therapies, which have shown promising results in slowing disease progression.
A growing awareness among the public and healthcare professionals about the importance of early diagnosis can drive significant advancements in these areas. Government initiatives aimed at improving healthcare access, combined with a significant rise in ophthalmology research and development, bolster the potential for growth in the Diagnosis and Treatment segment. The ongoing evolution of diagnostic devices and treatment options further reinforces the significance of this segment within the broader India Dry Age-Related Macular Degeneration (AMD) Market, presenting promising opportunities for market participants.
Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights
The India Dry Age-Related Macular Degeneration (AMD) Market, through the Route of Administration segment reflects diverse therapeutic approaches that are pivotal in managing this chronic eye condition. Oral formulations and injectables constitute the primary methods for delivering AMD treatments, each offering distinct benefits and implications for patient adherence and clinical outcomes. Oral medications are often favored for their ease of administration, promoting patient compliance and convenience, while injectables, particularly intravitreal injections, are recognized for their targeted action and effectiveness in delivering therapies directly to the affected area.
This phenomenon is increasingly critical in a population where AMD prevalence continues to rise, driven by an aging demographic and lifestyle factors. The rising awareness about vision health in India, supported by government initiatives and healthcare campaigns, furthers the importance of these delivery methods, especially as they align with ongoing Research and Development efforts to enhance treatment efficacy. Overall, as the focus on innovative therapies intensifies, understanding the precise dynamics of the Route of Administration will be essential in shaping the future landscape of the India Dry Age-Related Macular Degeneration (AMD) Market.
Dry Age-Related Macular Degeneration (AMD) Market End Users Insights
The India Dry Age-Related Macular Degeneration (AMD) Market is significantly influenced by its End Users, primarily hospitals and clinics, diagnostic centers, and academic and research institutes. Hospitals and clinics form a critical backbone for AMD management, providing essential care and treatment options to patients. Their extensive infrastructure facilitates early diagnosis and ongoing patient management, thus contributing to better health outcomes. Additionally, diagnostic centers play a pivotal role in the precise identification of AMD through advanced imaging techniques, which is vital for the timely initiation of treatment.
Academic and research institutes are crucial for the evolution of this field, driving innovation through Research and Development and improving understanding of AMD through studies and clinical trials. The collaboration among these segments fosters a robust ecosystem in the India Dry Age-Related Macular Degeneration (AMD) Market, addressing both patient needs and market growth. With the increasing prevalence of AMD and rising awareness regarding eye health, these End Users are poised to play an ever more significant role in shaping the landscape of AMD treatment and management across India.
India Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights:
The India Dry Age-Related Macular Degeneration (AMD) Market is characterized by various competitive dynamics fueled by the rising prevalence of age-related disorders and the growing elderly population. Numerous companies operate within this space, each vying for market share through innovative product offerings, strategic partnerships, and investment in research and development. The competitive landscape is further influenced by technological advancements, customer needs for improved treatment options, and the healthcare ecosystem's overall regulatory environment. Companies are also focusing on enhancing patient outcomes and addressing the challenges posed by this degenerative condition, thereby leading to increased competition.
Alcon holds a significant position in the India Dry Age-Related Macular Degeneration (AMD) Market and known for its strong commitment to ophthalmic surgeries and eye care products. The company’s strengths lie in its diversified portfolio of advanced treatment options, including surgical devices and pharmaceuticals specifically designed for retinal diseases. Alcon's extensive experience in the industry enables it to leverage its research capabilities to develop innovative solutions that address the unmet needs of AMD patients.
Furthermore, Alcon has established a robust distribution network across India, which enhances its market presence and allows for effective engagement with healthcare professionals and patients alike. This strong market footprint, combined with a commitment to quality and innovation, ensures that Alcon remains a formidable player in the landscape of AMD treatments in India.Zeiss also plays a crucial role in the India Dry Age-Related Macular Degeneration (AMD) Market, recognized for its expertise in optical and optoelectronic technologies. The company offers a range of key products that cater to AMD, including diagnostic instruments and advanced imaging solutions that aid in the early detection and monitoring of the disease.
Zeiss's strengths include its strong brand recognition and a longstanding reputation for precision and quality, which resonate well with both healthcare providers and patients. The company’s ongoing innovation efforts, coupled with strategic partnerships for research and development, bolster its competitive position in the market. In recent years, Zeiss has engaged in several collaborations aimed at expanding its product offerings and enhancing patient care solutions specific to AMD. These initiatives have not only strengthened its market presence in India but also facilitated its growth trajectory in line with the evolving demands of eye care professionals and their patients.
Key Companies in the India Dry Age-Related Macular Degeneration (AMD) Market Include:
- Alcon
- Zeiss
- CGI Pharma
- Horizon Therapeutics
- BristolMyers Squibb
- Apellis Pharmaceuticals
- Regeneron Pharmaceuticals
- Genentech
- Roches
- Santen Pharmaceutical
- HoffmannLa Roche
- Eyenovia
- Pfizer
- Bausch Health
- Novartis
India Dry Age-Related Macular Degeneration (AMD) Market Industry Developments
The India Dry Age-Related Macular Degeneration (AMD) Market has seen significant developments recently. The demand for innovative treatment options is increasing, driven by the growing aging population, which is a key contributor to AMD prevalence in India. In October 2023, Alcon launched a new diagnostic tool specifically tailored for early detection of AMD, enhancing early intervention capabilities. Moreover, Zeiss introduced advanced imaging technologies aimed at improving the understanding of AMD progression, further impacting diagnostics. In terms of mergers and acquisitions, there have been noteworthy movements; in July 2023, Horizon Therapeutics announced its acquisition of a biotech company specializing in ocular diseases, which could bolster its AMD product pipeline.
Furthermore, Regeneron Pharmaceuticals experienced a growth in its market valuation due to successful trial outcomes for its treatments aimed at retinal diseases, establishing it as a strong competitor in the AMD sector. The Indian government, recognizing the rising burden of eye diseases, is also pushing initiatives to improve healthcare services, which is expected to facilitate growth and accessibility of AMD treatments across the country.
India Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights
Dry Age-Related Macular Degeneration (AMD) Market Stage Outlook
- early age-related macular degeneration
- intermediate age-related macular degeneration
- late age-related macular degeneration
Dry Age-Related Macular Degeneration (AMD) Market Age Group Outlook
- above 75 years
- above 60 years
- above 40 years
Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Outlook
Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Outlook
Dry Age-Related Macular Degeneration (AMD) Market End Users Outlook
- hospitals & clinics
- diagnostic centers
- academic & research institutes
| Report Attribute/Metric Source: |
Details |
| MARKET SIZE 2018 |
220.0(USD Million) |
| MARKET SIZE 2024 |
240.0(USD Million) |
| MARKET SIZE 2035 |
600.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) |
8.687% (2025 - 2035) |
| REPORT COVERAGE |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR |
2024 |
| MARKET FORECAST PERIOD |
2025 - 2035 |
| HISTORICAL DATA |
2019 - 2024 |
| MARKET FORECAST UNITS |
USD Million |
| KEY COMPANIES PROFILED |
Alcon, Zeiss, CGI Pharma, Horizon Therapeutics, BristolMyers Squibb, Apellis Pharmaceuticals, Regeneron Pharmaceuticals, Genentech, Roches, Santen Pharmaceutical, HoffmannLa Roche, Eyenovia, Pfizer, Bausch Health, Novartis |
| SEGMENTS COVERED |
Stage, Age Group, Diagnosis and Treatment, Route of Administration, End Users |
| KEY MARKET OPPORTUNITIES |
Increasing elderly population, Rising awareness campaigns, Growth in telemedicine services, Advanced treatment innovations, Expanding healthcare infrastructure |
| KEY MARKET DYNAMICS |
increasing elderly population, rising awareness about AMD, advancements in treatment options, growing healthcare expenditure, government initiatives for eye health |
| COUNTRIES COVERED |
India |
Frequently Asked Questions (FAQ) :
The India Dry Age-Related Macular Degeneration (AMD) Market is expected to be valued at 240.0 USD Million in 2024.
By 2035, the market is projected to reach a value of 600.0 USD Million.
The expected CAGR for this market from 2025 to 2035 is 8.687%.
The intermediate age-related macular degeneration segment holds the highest value at 96.0 USD Million in 2024.
The early age-related macular degeneration segment is projected to have a market value of 180.0 USD Million by 2035.
Key players include Alcon, Zeiss, CGI Pharma, Horizon Therapeutics, and Bristol-Myers Squibb, among others.
The market faces challenges such as increasing competition and the need for innovative treatment options.
The market value for late age-related macular degeneration is expected to be 72.0 USD Million in 2024.
The intermediate age-related macular degeneration segment is expected to grow significantly to 240.0 USD Million by 2035.
Primary growth drivers include the aging population and increased awareness about eye health.
